MANGALAM DRUGS AND ORGANICS
|
|
BOM : 532637     NSE : MANGALAM     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Dec 04,2024 |
Price(EOD): ₹ 122.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 194.02 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MANGALAM DRUGS AND ORGANICS | 14.7% | 10.4% | 22.7% |
SUN PHARMACEUTICAL INDUSTRIES | 3.7% | -3.2% | 46.6% |
CIPLA | 0.6% | -3.7% | 26.7% |
DR REDDYS LABORATORIES | 1.9% | -3.4% | 5.8% |
ZYDUS LIFESCIENCES | 2.3% | -3.4% | 54% |
DIVIS LABORATORIES | 5.1% | 6.1% | 64% |
MANKIND PHARMA | 1.3% | -3.5% | 35.8% |
TORRENT PHARMACEUTICALS | 4.6% | 4.4% | 58% |
LUPIN | 5.1% | -4.4% | 62.5% |
FUNDAMENTAL ANALYSIS OF MANGALAM DRUGS AND ORGANICS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MANGALAM DRUGS AND ORGANICS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
20.64
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 9.42 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 1.37
P/B Calculated based on Book Value of Rs 142.35 Cr
[Latest Year - Mar2024 - Standalone Results ] 0.55
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
34% 12% 30% |
SHARE PRICE MOMENTUM OF MANGALAM DRUGS AND ORGANICS
MANGALAM DRUGS AND ORGANICS vs SENSEX
DEBT OF MANGALAM DRUGS AND ORGANICS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.67 0.49 0.52 0.56 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MANGALAM DRUGS AND ORGANICS
Pledged Promoter Shares |
18.08 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MANGALAM DRUGS AND ORGANICS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
4.45% 6.18% 103.93% -0.04% |
-1.98% 296.58% 125.14% 175.42% |
QtrlyTrend |
4 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
MANGALAM DRUGS AND ORGANICS related INDICES
You may also like the below Video Courses
FAQ about MANGALAM DRUGS AND ORGANICS
Is MANGALAM DRUGS AND ORGANICS good for long term investment?
As on Dec 04,2024, the Fundamentals of MANGALAM DRUGS AND ORGANICS look Poor and hence it may not be good for long term investment ! See Financial Performance of MANGALAM DRUGS AND ORGANICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MANGALAM DRUGS AND ORGANICS UnderValued or OverValued?
As on Dec 04,2024, MANGALAM DRUGS AND ORGANICS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MANGALAM DRUGS AND ORGANICS ?
As on Dec 04,2024, the Intrinsic Value of MANGALAM DRUGS AND ORGANICS is Rs. 94.64 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 91.97
Fair Value [Median EV / Sales Model] : Rs. 109.29
Fair Value [Median Price / Sales Model] : Rs. 94.64
Estimated Median Fair Value of MANGALAM DRUGS AND ORGANICS : Rs. 94.64
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.